Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 11:10:1482.
doi: 10.3389/fphar.2019.01482. eCollection 2019.

Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation

Lucy Meunier  1 , Dominique Larrey  1
Affiliations
Review

Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation

Lucy Meunier et al. Front Pharmacol. .

Abstract

The hepatotoxicity of drugs is the main cause of drug withdrawal from the pharmaceutical market and interruption of the development of new molecules. Biomarkers are useful in several situations. In case of suspected drug-induced liver injury (DILI), biomarkers can be used to confirm liver damage, its severity, prognosis, confirm drug causality, or define the type of DILI. In this review, we will first present the currently used biomarkers and candidate biomarkers for the future. The current biomarkers are certainly very helpful including with the assistance of diagnostic method such the Roussel Uclaf Causality Assessment Method, but provide a limited information for the early detection of liver injury, the role of specific drug and the prediction of DILI. Some biomarkers are promising but they are not yet available for routine use. Studies are still needed to confirm their interest, particularly in comparison to Roussel Uclaf Causality Assessment Method.

Keywords: RUCAM; biomarkers; drug-induced liver injury; hepatotoxicity; novel candidate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Current diagnostic biomarkers.
See this image and copyright information in PMC

References

    1. Aithal G. P., Ramsay L., Daly A. K., Sonchit N., Leathart J. B. S., Alexander G., et al. (2004). Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatol. Baltim. Md. 39 (5), 1430–1440. 10.1002/hep.20205 - DOI - PubMed
    1. Aithal G. P., Watkins P. B., Andrade R. J., Larrey D., Molokhia M., Takikawa H., et al. (2011). Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89 (6), 806–815. 10.1038/clpt.2011.58 - DOI - PubMed
    1. Andrade R. J., Robles M., Ulzurrun E., Lucena M. I. (2009). Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 10 (9), 1467–1487. 10.2217/pgs.09.111 - DOI - PubMed
    1. Andrade R. J., Aithal G. P., Björnsson E. S., Kaplowitz N., Kullak-Ublick G. A., Larrey D., et al. (2019). EASL clinical practice guidelines: drug-induced liver injury. J. Hepatol. 10.1016/j.jhep.2019.02.014 - DOI - PubMed
    1. Araújo A. M., Carvalho M., Carvalho F., Bastos M de, L., Guedes de Pinho P. (2017). Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI). Crit. Rev. Toxicol. 47 (8), 633–649. 10.1080/10408444.2017.1309638 - DOI - PubMed

LinkOut - more resources